Analgesics in China is expected to experience muted value performance in 2026, registering a marginal decline of 0.2% to CNY23,341 million, contrasting with the stronger growth observed across Asia Pacific. This subdued trajectory is primarily a result of entrenched preventative behaviour, expanded vaccination coverage and a consumer preference for professional healthcare, all of which continue to suppress demand for systemic analgesics. As volume-driven expansion becomes increasingly constrained by demographic headwinds and evolving health attitudes, the path to value resilience lies in rapid formulation innovation and digital transformation. Manufacturers and retailers are pivoting toward advanced product design, such as rapid-onset and gastric-friendly molecules, alongside investments in AI-driven consultation, online-to-offline delivery and personalised digital engagement. Rather than relying on traditional volume growth strategies, brands must blend technological agility with clinically substantiated product differentiation, targeting precise consumer needs through both advanced transdermal delivery systems and data-enabled retail experiences.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Overview:
Understand the latest market trends and future growth opportunities for the Analgesics industry in China with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in China, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
The Analgesics in China report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volume and value sizes, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent research methodology, conducted in-country
This report answers:
- What is the market size of Analgesics in China?
- Which are the leading brands in Analgesics in China?
- How are products distributed in Analgesics in China?
- How has the regulatory and operating environment for Analgesics changed in China?
- How are considerations such as stress, self-medication and shifting consumer lifestyles shaping demand for Analgesics
- How significant are wider health concerns and consumer awareness in determining sales?
- Where is future growth expected to be most dynamic?
Key Data Insights
Key Industry Trends
Suppressed demand for systemic analgesics constrains sales growth
JD Health and LBX Pharmacy drive digital channel transformation through AI integration
Preventative behaviour and digital innovation suppress volume, but support value resilience
Chart 1 Value Sales 2021-2031
Chart 2 Value Sales by Category 2026
Rapid-onset innovation is set to reshape demand
Advanced transdermal delivery lifts topical analgesics
O2O platforms and AI-driven personalisation accelerate innovation
Chart 1 Forecast Value Sales 2021-2031
Chart 2 Forecast Value Sales by Category 2026-2031
Yunnan Baiyao strengthens leadership as rivals face demand pressure
Chart 1 Company Shares 2026
Chart 2 Brand Shares 2026
Trusted advice boosts pharmacies’ appeal
LBX Pharmacy and O2O platforms redefine retail engagement
Chart 1 Retail Channels 2021-2026
Renhe Yikang and JD Health shape the future with formulation and digital breakthroughs
Yunnan Baiyao and LBX Pharmacy secure leadership through transdermal and AI-driven strategies
Chart 1 Real GDP Growth 2021-2031
Chart 2 Inflation 2021-2031
Chart 1 Population 2021-2031
Chart 2 Population by Generation 2026
Chart 3 Consumer Expenditure 2021-2031
Country Reports Disclaimer
The following categories and subcategories are included:
Analgesics
-
-
- Adult Acetaminophen
- Adult Aspirin
- Adult Combination Products - Analgesics
- Adult Diclofenac
- Adult Dipyrone
- Adult Ibuprofen
- Adult Ketoprofen
- Adult Naproxen
- Adult OTC Triptans
-
- Paediatric Acetaminophen
- Paediatric Aspirin
- Paediatric Combination Products - Analgesics
- Paediatric Dipyrone
- Paediatric Ibuprofen
- Paediatric Naproxen
-
- Acetaminophen
- Aspirin
- Combination Products - Analgesics
- Diclofenac
- Dipyrone
- Ibuprofen
- Ketoprofen
- Naproxen
- OTC Triptans
-
- Topical Analgesics/Anaesthetic
Analgesics
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).
See all of our definitionsWhy buy this report?
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
This report originates from Passport, our Analgesics research and analysis database.
NEW REPORT GUARANTEE
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!